News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cempra Pharmaceuticals, Inc. Presents Late-Breaker On Solithromycin's Anti NASH Effects In An Animal Model At DDW 2014



5/6/2014 10:03:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHAPEL HILL, N.C., May 6, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin significantly reduced ballooning degeneration and inflammation which are histological signs of non-alcoholic steatohepatitis (NASH) in an animal model at Digestive Disease Week (DDW) in Chicago. The abstract titled, "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," will be presented at 9:15 a.m. CDT, Tuesday, May 6, in Room S015A at McCormick Place in Chicago.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES